Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer (NCT04603365) | Clinical Trial Compass
WithdrawnPhase 2
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Stopped: enrollment
0Started 2021-10-18
Plain-language summary
This phase II trial investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer. Poly adenosine diphosphate-ribose polymerase (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as pamiparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pamiparib and temozolomide may help treat patients with hereditary leiomyomatosis and renal cell cancer.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject has voluntarily agreed to participate by signing an informed consent
* Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1
* Ability to swallow whole capsules
* Histologically confirmed metastatic or unresectable renal cell carcinoma with morphologic features consistent with hereditary leiomyomatosis and renal cell cancer (HLRCC). This can include tumors with overlapping morphology previously called papillary, tubulocystic, tubulopapillary, collecting duct, or unclassified as long as in the HLRCC- spectrum
* The presence of a documented germline fumarate hydratase (FH) alteration (mutation or deletion). This includes pathogenic or likely pathogenic alterations but may also include variants of unknown significance (VUS) in patients with strong personal or family history where the clinician makes a presumed clinical diagnosis
* Progression on 1 or more lines of systemic therapies for metastatic disease. Neo/adjuvant therapy in the absence of documented distant disease does not count as a line of therapy
* No known intolerance of study drugs or excipients, and able to comply with study requirements
* Absolute neutrophil count (ANC) \>= 1,500 /microliter (mcL) (\< 2 weeks prior to day 1)
* Platelets \>= 100,000 / mcL (\< 2 weeks prior to day 1)
* Hemoglobin \>= 10 g/dL or \>= 6.2 mmol/L without transfusion or erythropoietin (EPO) dependency (within 2 weeks of first dose)
* Serum creatinine =\< 1.5 x upper limit of normal (ULN) OR mā¦